Karvea (Irbesartan)

Irbesartan blocks the angiotensin II type 1 (AT1) receptors, preventing angiotensin II from causing blood vessels to narrow and from stimulating aldosterone release. This leads to vasodilation, reduced sodium‑water retention, and lower blood pressure.

The appropriate dose of Karvea is determined by the prescribing clinician based on the individual’s blood‑pressure goals, kidney function, and other medical factors. Patients should follow the dosage instructions provided by their healthcare professional.

Irbesartan is classified as contraindicated in pregnancy because it can cause fetal toxicity, especially in the second and third trimesters. Safety during breastfeeding has not been established, so use is generally avoided unless the benefit outweighs the risk.

To request Karvea, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Karvea belongs to the ARB class, which offers blood‑pressure control similar to ACE inhibitors but with a lower incidence of cough and angioedema. Compared with calcium‑channel blockers, ARBs act on the renin‑angiotensin system rather than directly relaxing vascular smooth muscle.

Karvea tablets should be stored at ambient temperature, below 25 °C, in their original blister pack or container. Protect them from moisture, excessive heat and direct sunlight to maintain potency throughout the shelf life.

Karvea is taken orally, usually once daily, with or without food. Patients should swallow the tablet whole with a glass of water and avoid crushing or chewing unless specifically instructed by a healthcare professional.

The most serious adverse events include angioedema (swelling of the face, lips, tongue), severe hyperkalemia, acute kidney injury, and symptomatic hypotension. Any sudden swelling, difficulty breathing, or marked drop in blood pressure warrants immediate medical attention.

Karvea should not be used by individuals with known hypersensitivity to irbesartan or any ARB, pregnant women, patients with severe hepatic impairment, or those with uncontrolled hyperkalemia. Clinicians should also exercise caution in patients with severe renal artery stenosis.